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Abstract
Background: We describe the epidemiology and antimicrobial susceptibility patterns of culture-confirmed Shigella
infections in facility-based surveillance sites in Guatemala. Current studies using quantitative molecular diagnostics
suggest Shigella may contribute most to the global diarrheal disease burden. Since identification of Shigella requires
culturing techniques using stool specimens and few laboratories in Guatemala routinely culture for this pathogen,
little is known about the true burden of Shigella in Guatemala or, importantly, the antimicrobial resistance patterns.
Methods: Clinical, epidemiological, and laboratory data were collected on 5399 patients with acute diarrhea (≥3
loose stools in 24 h) from June 2007–August 2012. Multidrug resistance (MDR) was defined as resistance to
ampicillin and trimethoprim/sulfamethoxazole.
Results: Five percent (261) of stool specimens yielded Shigella spp. The annual incidence of laboratory-confirmed
infections ranged from 5.0 to 24.1 per 100,000 persons in Santa Rosa and 0.3 to 6.2 per 100,000 in Quetzaltenango;
58% of cases occurred in children < 5 years of age. Thirty patients were hospitalized; one patient died. Oral
rehydration or intravenous solution was used to treat 72% of hospitalized and 15% of ambulatory cases. Fifty-nine
percent of cases were S. flexneri and 51% of cases were MDR.
Conclusions: Shigella is an important cause of bacterial diarrhea in children and prevalence of MDR highlights the
importance of appropriate treatment regimens. This study demonstrates that strengthening laboratory capacity in
Guatemala can help determine causes which can lead to prevention of diarrheal diseases, particularly in children.
Such capacity building is also critical for rapid detection and control of public health threats at their source and
therefore for global health security.
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Background
Globally, diarrheal infections resulted in an estimated
688 million illnesses in 2015, and 499,000 deaths in chil-
dren under 5 years of age [1, 2]. Despite dramatic reduc-
tions in childhood mortality in the past decade, diarrhea
remains a major cause of preventable childhood deaths
worldwide [3, 4], and still leads to higher risk of growth
faltering and other health effects in those children that
survive [5]. Shigella is one of four primary pathogens
that substantially contributes to moderate and severe
diarrhea globally [6, 7]. Indeed, quantitative molecular
diagnostics suggest Shigella may contribute most to the
global diarrheal disease burden [8]. While case fatalities
have significantly decreased over time, morbidity from
shigelloses remains an important problem and warrants
investments in surveillance to better understand anti-
biotic resistance, treatment options, and preventive mea-
sures, including vaccine development [9].
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Characterized by fever, abdominal pain, tenesmus, and
loose stools, Shigella is usually acquired by ingestion of
contaminated food or water [10]. In addition to the high
mortality [11], sequelae of shigellosis can include enceph-
alopathy, hemolytic uremic syndrome, bacteremia, dysen-
tery, rectal prolapse [12], hypoglycemia, hyponatremia
[13], and reactive arthritis [10, 14]. Children may experi-
ence high fever with convulsions [12]. Though previous
studies have demonstrated the effectiveness of certain an-
timicrobials as treatment, resistance to commonly used
antimicrobials such as trimethoprim/sulfamethoxazole,
ampicillin, third generation cephalosporins, quinolones
and macrolides [15–18] complicates treatment for those
with severe disease [12, 19]. Additionally, fluoroquino-
lones, which may be effective, are not recommended for
children and pregnant women [19]. Shigellosis may also
be confused with acute amoebic dysentery, leading to in-
appropriate treatment with metronidazole or tinidazole
[19]. Lastly, the diversity of Shigella serotypes has historic-
ally rendered vaccine development difficult [15].
In Guatemala, diarrhea remains the second most
common cause of morbidity and mortality in children
< 5 years of age [20], and small, community-based
studies implicate Shigella as a common cause of diar-
rhea [21, 22]. However, since identification of Shigella
requires culturing techniques using stool specimens
[10] and few laboratories in Guatemala routinely cul-
ture for this pathogen, little is known about the true
burden of Shigella in Guatemala or the antimicrobial
resistance patterns. Limited laboratory capacity in
Guatemala also results in delays in detecting, or an
inability to recognize, outbreaks of Shigella infec-
tions, in addition to illnesses caused by other patho-
gens. Thus, controlling such outbreaks at their
source is difficult, thereby threatening global health
security. In this report, we characterize cases of
laboratory-confirmed shigellosis enrolled in a health-
care facility-based surveillance system in Guatemala
from 2007 through 2012 in order to inform preven-




In July 2007, the U.S. Centers for Disease Control and
Prevention International Emerging Infections Program
(CDC IEIP), the Guatemalan Ministry of Public Health
and Welfare (MSPAS), and the Center for Health Studies
of the Universidad del Valle de Guatemala (UVG) initi-
ated an active facility-based surveillance system for diar-
rheal, respiratory, acute neurologic infections, and
non-differentiated febrile illnesses in the department of
Santa Rosa [23]. The surveillance system, Vigilancia Inte-
grada Comunitaria (VICo), captured patients in both
ambulatory and hospital settings. An additional site was
added in February 2009 in the department of Quetzalte-
nango. Santa Rosa is located in the southern part of the
country with a population of 346,590 in 2002, and Quet-
zaltenango is in the western highlands with a population
of 789,358 [24]. Compared with Quetzaltenango, Santa
Rosa has a lower elevation (1219m vs. 2438m at the
hospitals), higher average temperature, higher average
rainfall, and a smaller proportion of the population is
Amerindian indigenous (15% versus 62%).
In Santa Rosa, the facility-based surveillance system in-
cluded the Cuilapa Regional Hospital, one health center
staffed by a physician and nurses, and five health posts,
each staffed by a nurse. The Cuilapa Regional Hospital is a
176-bed referral hospital that provides care for residents
of Santa Rosa and the neighboring departments of Jutiapa
and Jalapa. In Quetzaltenango, the surveillance system in-
cluded the Western Regional Hospital, three health cen-
ters, and one health post. The Western Regional Hospital
is a 425-bed referral hospital that provides care for Quet-
zaltenango and the neighboring departments of Huehue-
tenango, San Marcos, Totonicapan, among other
departments in Guatemala and Mexico. Health centers
and health posts in both departments were considered
ambulatory care. Private clinics, small private hospitals,
pharmacies, traditional healers, and one public hospital in
coastal Quetzaltenango make up the other sources of
healthcare in the two departments.
Case detection and data collection
A case of diarrhea was defined as ≥3 loose or liquid
stools in a 24-h period with onset of illness within seven
days before presenting to any participating facility. Inclu-
sion criteria included residence in one of the municipal-
ities included in the surveillance system. Cases with
other diarrheal episodes within one week prior to the
start of the current episode were excluded to avoid cap-
turing illnesses due to chronic diarrhea. Surveillance
nurses screened patients by reviewing logbook entries
and assessed chief complaints for diarrhea-related visits
and admissions. Detailed clinical, epidemiologic,
demographic, and socioeconomic data were obtained
from structured patient interviews and medical chart
abstractions [25].
Laboratory methods
All consenting patients were requested to provide
bulk stool specimen. Rectal swabs were performed on
children < 5 years of age who were unable to provide
a specimen. Stool samples from the ambulatory facil-
ities were then stored in Cary-Blair transport media
at 4 °C and transported at 4 °C within 48 h to one of
the two regional hospitals for initial processing and
testing. Samples were subsequently streaked by direct
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plating onto selective agars, MacConkey and
Xylose-lysine-desoxycholate (XLD) [26]. After incuba-
tion, colonies suggestive of Shigella (lactose negative
colonies) were tested biochemically with Triple Sugar
Iron (TSI), lysine iron (LIA), Sulfide-indole-motility
(SIM) medium, Motility-indole-ornithine (MIO)
medium, citrate, and urea. If the result of the bio-
chemical test then suggested the colony examined
was Shigella positive, the isolate was then tested with
antisera for the different Shigella species.
At the hospital laboratories, antimicrobial susceptibility
testing was performed on Shigella isolates using the disk
diffusion method with the following antibiotics: ampicillin,
amoxicillin, ceftriaxone, gentamicin, kanamycin, strepto-
mycin, ciprofloxacin, nalidixic acid, chloramphenicol, tri-
methoprim/sulfamethoxazole and tetracycline, using
Clinical Laboratory Standards Institute (CLSI) breakpoints
[27]. Multidrug-resistance (MDR) was defined as resist-
ance to at least ampicillin and trimethoprim/sulfameth-
oxazole, an important MDR phenotype for Shigella [11].
Samples were later sent to serotyping. The isolates were
serotyped by slide agglutination tests using specific anti-
sera at UVG laboratories (Denka Seiken Co, Ltd.).
Data analysis
We examined the number of laboratory-confirmed Shi-
gella cases identified in the surveillance system from July
2007 to August 2012 in Santa Rosa and from February
2009 to August 2012 in Quetzaltenango. We described
the temperature and rainfall in each department during
this period. Population-based annual crude incidence
rates for Shigella were calculated by using the detected
number of cases and catchment area population of the
surveillance health facilities. Incidence rates were calcu-
lated from 2008 to 2012 for Santa Rosa, due to surveil-
lance starting mid-year in 2007 in Santa Rosa. Incidence
rates were calculated from 2009 to 2012 for Quetzalte-
nango. Population by municipality and age were ob-
tained from the Guatemala National Institute of
Statistics [24]. Population estimates for 2011 and 2012
were extrapolated from 2010 population data. As the
catchment area for each surveillance site did not include
all municipalities within a department, we used popula-
tion estimates for only municipalities in our catchment
area for the incidence denominator. The catchment area
for the Cuilapa Regional Hospital included 11 munici-
palities in Santa Rosa Department, excluding the three
coastal municipalities. The catchment area in Quetzalte-
nango included 10 municipalities, including Quetzalte-
nango city. Crude incidence rates were calculated across
all ages and for children < 5 years of age. Poisson-based
95% confidence intervals were calculated for the annual
rates of Shigella. The last year of surveillance was ad-
justed to account for eight months of observation. We
also calculated adjusted incidence rates to account for
differences in healthcare seeking behavior between hos-
pitals and ambulatory care; we calculated different esti-
mates of incidence based on cases that were detected at
a hospital versus health center or post.
We described the demographic characteristics, symp-
toms, co-infections, and treatment of Shigella cases
stratified by ambulatory and hospital settings for both
Santa Rosa and Quetzaltenango. Chi-square or Fisher’s
exact test were used to determine differences in charac-
teristics between ambulatory and hospital settings.
T-tests or analysis of variance (ANOVA) was used to test
differences in means for continuous variables. We exam-
ined the number of days hospitalized patients spent in
the intensive care unit, total length of hospital stay, and
case fatality.
We characterized Shigella cases by serotype. Within
each serotype, we counted the number of cases that
were hospitalized and that reported bloody stool.
Chi-square tests of proportions were used to determine
differences across serotypes. Without comparative data
from the underlying population at risk, we only assessed
the proportion of Shigella cases according to potential
risk factors, including education, safe water use, breast-
feeding, refrigerator use, and large household size.
Lastly, we reported the percent resistant to the anti-
microbial classes and those with MDR. We also evalu-
ated differences in antibiotic resistance between the
surveillance sites and across time.
Results
From 2007 to 2012, stool samples from 5399 patients
yielded 261 cases of Shigellosis, of which 91% were re-
ported from the Santa Rosa department. Sixty-two per-
cent of Shigella infections occurred from May to
October (Fig. 1). Greater than half of all Shigella cases
(58%) occurred in children < 5 years of age with a me-
dian age of 3 years (range: 1 month to 91 years); 149
(57%) were female (Table 1). Thirty (12%) patients with
Shigellosis were hospitalized; 25 (83%) of the hospitalized
patients were < 5 years of age and 4 (13%) were aged
≥60 years. Among ambulatory cases, 126 (55%) were < 5
years of age and 7 (3%) were aged ≥60 years. Hospital-
ized patients were significantly younger than ambulatory
patients (p < 0.001). A greater proportion of hospitalized
patients reported vomiting (p < 0.0001) and had convul-
sions and lethargy (p < 0.05). Parasites were observed in
stool samples of 30% of patients with Shigella. Eighteen
(72%) hospitalized cases were treated with oral rehydra-
tion salts or intravenous solution. Among hospitalized
cases, the median hospital stay was 4 days. Six cases
(20%) were admitted to the intensive care unit and one
case died. The case that died was a one-year old child in
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Santa Rosa with S. flexneri; no co-morbidities or treat-
ment regimen was reported for this case.
The education level of the parents of children < 5 years
of age was low with 94% having no or only basic educa-
tion (up to 9th grade). Overall, 67% of families reported
monthly income of under $130/month. Only 37% of all
cases reported having a refrigerator at home and over
60% of cases came from households of more than five
people. In both the hospital and ambulatory setting, 78%
of cases < 2 years were breastfed. A majority of cases re-
ported using the public and municipal water sources,
and also home storage of water.
The crude annual incidence rate of Shigella cases
ranged from 13.8 to 24.1 per 100,000 from 2008 to
2012 in the Santa Rosa Department for all ages, and
52.3 to 91.9 per 100,000 persons for children < 5 years
for both hospital and ambulatory cases (Table 2). Am-
bulatory care incidence estimates are higher for both
children < 5 years and all ages than hospital care in
Santa Rosa; the annual incidence rate of Shigella
cases ranged from 348.2 to 594.5 cases for children <
5 years and 108.1 to 174.0 cases for all ages
(Additional file 1). In Quetzaltenango, the crude an-
nual incidence rates ranged from 0.3 to 6.2 per
100,000 persons from 2009 to 2012 for all ages, and
0 to 31.1 per 100,000 persons for children < 5 years
(Table 2). The adjusted annual incidence in ambula-
tory care was as high as 92.5 cases for children < 5
years and 22.1 cases for all ages in Quetzaltenango
(Additional file 1). In Quetzaltenango, there are more
cases in 2012 than in previous years.
The most frequently isolated serotypes were Shigella
flexneri (59%) and Shigella sonnei (36%). Among 30 hos-
pitalized patients, 25 (83%) were infected with S. flexneri
compared to 4 with S. sonnei (13%) and one with S. boy-
dii. Among those cases with S. flexneri, 36% reported
having bloody stool; 20% of S. sonnei cases reported
having bloody stool.
Fig. 1 Seasonality of Shigella cases relative to average temperatures and monthly rainfall, 2007–2012 in Santa Rosa and Quetzaltenango
Departments, Guatemala. *Peak season of cases and rainfall is from May to October. †This peak is largely from an outbreak at a single birthday
party. ‡Surveillance started in February 2009 in Quetzaltenango.
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Antimicrobial susceptibility testing was performed on
254 of the 261 laboratory-confirmed Shigella cases
(Table 3). Resistance to ampicillin was detected in 61%
of the isolates and resistance to trimethoprim/sulfameth-
oxazole in 83%; 120 (51%) cases were resistant to both
(MDR). Sixty-three percent of cases in Santa Rosa were
resistant to ampicillin as compared to 35% in Quetzalte-
nango, and 86% of cases in Santa Rosa were resistant to
trimethoprim/sulfamethoxazole as compared to 52% in
Quetzaltenango (Additional file 2). Fifty-five percent
of cases were resistant to both ampicillin and tri-
methoprim/sulfamethoxazole (SMX/TMP) in Santa
Rosa versus 13% in Quetzaltenango. Both resistance to
ampicillin and MDR increased over the surveillance
time period from 2007 to 2012 (Additional file 3). All
isolates were resistant to at least one antimicrobial
class tested; none were resistant to ciprofloxacin.
Eighty percent of all isolates were resistant to at least














Female 149 (57.1) 14 (46.7) 135 (58.4) 0.22
Age
0 to 6 months 2 (0.8) 1 (3.3) 1 (0.4) 0.001
6 months to < 1 year 16 (6.1) 5 (16.7) 11 (4.8)
1 to 4 years 133 (50.9) 19 (63.2) 114 (49.5)
5 to 9 years 36 (13.8) 1 (3.3) 35 (15.2)
10 to 20 years 29 (11.1) 0 (0.0) 29 (12.6)
20 to 40 years 25 (9.6) 0 (0.0) 25 (10.8)
40 to 60 years 9 (3.5) 0 (0.0) 9 (3.9)
60 + years 11 (4.2) 4 (13.3) 7 (3.0)
Symptoms
Under 5 years 151 (100.0) 23 (100.0) 128 (100.0)
Vomiting 42 (28.0) 17 (74.0) 25 (37.8) < 0.0001
Unable to drink or breastfeed 71 (47.0) 15 (60.0) 56 (44.1) 0.15
Convulsions 5 (4.0) 3 (13.0) 2 (2.2) 0.024
Lethargy 57 (36.0) 3 (12.0) 54 (40.0) 0.007
All ages
Temperature in oC Median (Range) 37 (34.4–40) 37 (36–39.5) 36.9 (34.4–40)
Vomiting 99 (38.1) 21 (70.0) 78 (33.9) < 0.0001
Abdominal Pain 185 (71.2) 11 (37.0) 174 (75.7) < 0.0001
Bloody stool 80 (30.8) 5 (17.0) 75 (32.6) 0.19
Mucoid stool 183 (70.4) 15 (50.0) 168 (73.0) 0.009
Co-Infections
Campylobacter coli 2 (0.8) 0 (0.0) 2 (0.9) 0.61
Campylobacter jejuni 4 (1.5) 0 (0.0) 4 (1.7) 0.47
Rotavirus 3 (1.3) 3 (10.0) 0 (0.0) < 0.0001
Any protozoa or helminth 78 (30.0) 6 (20.0) 72 (31.6) 0.19
Giardia 5 (1.9) 0 (0.0) 5 (2.2) 0.41
Treatmentb
Oral rehydration salts or solution 37 (25.0) 18 (72.0) 19 (15.0) < 0.0001
aProportions based on non-missing data
bNot sufficient antibiotic data for treatment. 18 patients had other treatment, 4 had antibiotics and 9 had salts/solution
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three antimicrobial classes. There were no remarkable
differences in antimicrobial resistance between
hospital and ambulatory cases.
Discussion
We characterized laboratory-confirmed Shigella cases
captured by a facility-based surveillance system in Santa
Rosa and Quetzaltenango, Guatemala. There are five
characteristics among our findings that are pertinent to
prevention and treatment of Shigellosis in Guatemala:
age of infection, seasonality and region, species of Shi-
gella, antimicrobial resistance, and antibiotic and rehy-
dration treatments.
Most patients with Shigella presented to ambulatory
care centers for treatment, and consistent with the
known epidemiology of Shigella, we found the greatest
burden of disease among young children [15]. Compared
to the United States, the annual incidence of Shigella
was higher for all ages and children < 5 years of age in
Santa Rosa but not in Quetzaltenango [28, 29]. Inci-
dence rates from active surveillance in Santa Rosa were
23.4–91.1 cases per 100,000 in children aged < 5 years
compared with 16.9 cases per 100,000 reported in the
U.S. [29]. Though higher than those of the U.S., rates in
Guatemala were lower than those of Africa and Asia
[30]. Still, the adjusted incidence estimates in this study
revealed children < 5 years as an important age group,
particularly in the ambulatory setting. Though children
under 5 years comprised 58% of all cases and 80% of
those hospitalized, 13% of those hospitalized were ≥ 60
years of age. Prevention of this food and waterborne in-
fection must be targeted to protect the most vulnerable
populations, that is, children and the elderly. Prevention
measures like breastfeeding should be encouraged for
children < 2 years, as recommended by the World Health
Organization (WHO) [31].
There were large differences in the crude annual inci-
dence rates of Shigella and antibiotic resistance patterns
by department. Since higher temperatures allow bacteria
to reproduce at a higher rate, the warm climate of Santa
Rosa department may have contributed to the higher rate
of food and waterborne disease [32, 33]. Moreover, most
cases occurred during the warm, rainy season from May–
October, indicating that special care must be taken in
high-risk areas during this time to prevent transmission.
Studies from China and Israel and the United States, as
reported by the National Antimicrobial Resistance Moni-
toring System for Enteric Bacteria (NARMS) or other
CDC surveillance, also found a seasonally higher rate of
Shigella during periods of higher temperatures [33–35].
Such prevention tactics may include safe water and hy-
giene practices at the individual and household level,
Table 2 Crude incidence rates of Shigella by site and age group in Santa Rosa and Quetzaltenango Departments, Guatemala, 2008–
2012
Santa Rosa Quetzaltenangob
Number of Cases Crude Incidence Rate per 100,000 Population
(95% CI)a
Number of Cases Crude Incidence Rate per 100,000 Population
(95% CI)a
Overall 231 15.1 (13.2, 17.1) 23 1.2 (0.76, 1.79)
2008
< 5 years 34 91.9 (63.7, 128.4)
All ages 52 21.1 (15.8, 27.7)
2009
< 5 years 32 85.6 (58.5, 120.8) 0 0.0 (0.0, 7.5)
All ages 54 21.5 (16.2, 28.1) 1 0.3 (0.008, 1.7)
2010
< 5 years 26 68.8 (45.0, 100.8) 1 1.8 (0.05, 10.0)
All ages 46 18.0 (13.2, 24.0) 2 0.5 (0.07, 2.0)
2011
< 5 years 20 52.3 (32.0, 80.8) 3 5.3 (1.1, 15.5)
All ages 36 13.8 (9.7, 19.1) 4 1.1 (0.29, 2.7)
2012c
< 5 years 18 69.7 (41.3, 110.1) 12 31.1 (16.1, 54.4)
All ages 43 24.1 (17.5, 32.5) 16 6.2 (3.5, 10.0)
a95% CI represents Upper Limit (UL), Lower Limit (LL)
bSurveillance in Quetzaltenango began in 2009
cRates account for partial year through August 31
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which for decades has been proven as an effective prevent-
ive measure for diarrheal disease [36, 37]. Special care in
human feces disposal and prevention of transmission by
hands, fomites and insects is essential. Low levels of edu-
cation, however, and crowding at the household level may
be obstacles to implementing prevention measures as
these factors have been shown to increase diarrheal dis-
ease risk [38, 39]. Of note, the rates in Santa Rosa in-
creased in 2012 as a result of an outbreak at a children’s
birthday party involving 17 persons.
Similar to the rest of the world, the observed percent-
age of S. flexneri was approximately 60%; S. flexneri pre-
dominates in low-income countries [15]. However, S.
sonnei (35%) is twice as high in our study as compared
to global estimates for low-income countries (15%) [15].
Interestingly, in industrialized countries, S. sonnei is
closer to 77% of Shigella infections while S. flexneri is
16% of Shigella infections, suggesting that Guatemala is
in a developmental transition [15]. Fortunately, the epi-
demic of Shigella dysenteriae that affected much of
Central America in the 1960s [40] and Guatemala in the
1990’s has abated [41]. Only one isolate of S. dysenteriae
was detected in our surveillance.
Among isolates tested in our surveillance system in
Guatemala, antimicrobial resistance to commonly used
antimicrobials was high, as was the proportion that was
resistant to at least three antimicrobial classes. The pro-
portion of isolates that were resistant to at least ampicil-
lin and SMX/TMP (51%) in Guatemala is markedly
higher than in the United States (16%), as reported by
NARMS in 2012 [11]. Because a majority of isolates of
Shigella were resistant to accessible and inexpensive oral
treatments like trimethoprim/sulfamethoxazole (83% re-
sistant) and ampicillin (61% resistant), antimicrobial
treatment options are limited in Guatemala. Though
quinolones are effective and no resistance to ciprofloxa-
cin was found in our study, quinolones have side effects
such as joint and tendon injury, and are not generally
used in children. In Bangladesh, there have been
marked increases in resistance to ciprofloxacin [42].
This trend has also been noted in China, Canada,
and the United States [11, 30, 43, 44]. Of note, re-
sistance of Shigella to commonly used antibiotics in
Guatemala, while greater than reported in the U.S.
[11], is similar to that reported in other American
countries including Mexico and Chile [43, 45].
Table 3 Antimicrobial resistance by Shigella serotypes in Guatemala, 2007–2012















Aminoglycoside Gentamicin 3 (1.0) 1 (1.0) 1 (1.0) 1 (8.0) 0 (0.0)
Kanamycin 4 (2.0) 2 (3.0) 2 (2.0) 0 (0.0) 0 (0.0)
Streptomycin 212 (85.0) 87 (99.0) 112 (76.0) 11 (92.0) 2 (100.0)
Beta-lactams Ampicillin 141 (61.0) 45 (58.0) 87 (61.0) 8 (67.0) 1 (50.0)
Amoxicillin 117 (47.0) 36 (41.0) 72 (49.0) 8 (67.0) 1 (50.0)
Ceftriaxone 3 (2.0) 1 (2.0) 1 (1.0) 0 (0.0) 1 (50.0)
Quinolones Ciprofloxacin 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Nalidixic acid 1 (0.4) 0 (0.0) 1 (1.0) 0 (0.0) 0 (0.0)
Phenicol Chloramphenicol 37 (15.0) 2 (2.0) 35 (23.0) 0 (0.0) 0 (0.0)
Sulfonamide Trimethoprim sulfamethoxazole 210 (83.0) 82 (93.0) 118 (78.0) 9 (75.0) 1 (50.0)
Tetracycline Tetracycline 238 (96.0) 83 (94.0) 143 (97.0) 10 (91.0) 2 (100.0)















No resistance 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Resistance to one antimicrobial class 15 (5.9) 3 (3.4) 12 (7.9) 0 (0.0) 0 (0.0)
Resistance to two antimicrobial classes 37 (14.6) 2 (2.3) 31 (20.4) 3 (25.0) 1 (50.0)
Resistance to three antimicrobial classes 66 (26.0) 39 (44.3) 24 (15.8) 3 (25.0) 0 (0.0)
Resistance to four antimicrobial classes 121 (47.6) 42 (47.7) 73 (48.0) 6 (50.0) 0 (0.0)
Resistance to five antimicrobial classes 15 (5.9) 2 (2.3) 12 (7.9) 0 (0.0) 1 (50.0)
Multidrug-resistanceb 120 (51.3) 44 (56.4) 68 (47.9) 7 (58.3) 1 (50.0)
aProportions based on non-missing data
bResistance to ampicillin and trimethoprim-sulfamethoxazole (AT/S)
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While azithromycin is a first-line antibiotic treatment
in the U.S. [16] and could be considered for treatment
in Guatemala, it is important to note that resistance of
Shigella to ampicillin and amoxicillin, both penem
beta-lactam antibiotics, increased over the course of the
surveillance period from 2007 to 2012. MDR resistance,
resistance to both ampicillin and SMX/TMP, also in-
creased over the surveillance period, limiting their thera-
peutic utility, especially in Santa Rosa. Continued
surveillance of these dynamics is critical for understand-
ing both prevention and treatment.
In addition to treatment with effective antibiotics, re-
hydration with oral rehydration solutions is a critical
form of treatment [46]. Our findings, however, suggest
that a substantial number of patients with Shigellosis
were not treated with oral rehydration solution. Oral re-
hydration is an inexpensive and effective method that
should be emphasized through education and policy.
Our findings are subject to limitations. These data
apply only to the Departments of Santa Rosa and
Quetzaltenango and therefore are not generalizable to
all of Guatemala. However, they are the most compre-
hensive description of Shigella in Guatemala and Cen-
tral America in the healthcare setting. As treatments
are self-reported, information bias is a limitation of
the reported use of rehydration therapies. Such bias,
however, would indicate there are systematic differ-
ences among all cases and would neither over- or
under-estimate treatment use. Furthermore, Shigella
testing was done by standard cultures and not quanti-
tative real-time polymerase chain reaction (PCR) due
to resource constraints, suggesting the burden of dis-
ease estimates in this analysis are likely an underesti-
mate of the true value [9]. By re-analyzing samples or
subscribing to a quantitative real-time PCR detection
method, the detection capability of Shigella would im-
prove significantly and additionally aid in the current
development of a vaccine against Shigella spp. The
high detection rate of these species in samples should
be prioritized as vaccination of children in early life
could be greatly beneficial [3, 47].
Additionally, although healthcare utilization surveys in
the same region in Guatemala demonstrated that a major-
ity of patients sought care for their illness outside the
home, less than a quarter of all cases and only 51% of chil-
dren sought care at a government health facility [23, 48].
This indicates again that our estimates of Shigella cases
are likely an underestimate of the true burden of disease
in the population. Also, though the surveillance platform
included the main hospital in each department, the ambu-
latory facilities were limited in Santa Rosa to five clinics in
one municipality (Nueva Santa Rosa) and in Quetzalte-
nango to three municipalities. Not all patients sought care
in those facilities. Patients seen in the emergency
department but not admitted to the hospital were not cap-
tured by the surveillance system. As a result, our crude
and adjusted disease rates may further be an underesti-
mate of the true rates of Shigella disease.
Conclusion
This study demonstrates that Shigella is an important
cause of enteric infections in Santa Rosa and Quetzalte-
nango, Guatemala, especially in children < 5 years of age.
Shigella flexneri and S. sonnei were the most common
species while S. dysenteriae was rare. Antibiotic resistance
to commonly used antibiotics was prevalent and compli-
cates treatment. This study demonstrates the importance
of strengthening laboratory capacity in Guatemala for de-
termining causes that can lead to prevention of diarrheal
diseases, particularly in children. Such capacity building is
also critical for rapid detection and control of public
health threats at their source, and therefore for global
health security. Future steps should include strengthening
laboratory surveillance for antibiotic resistance patterns in
the region, implementation of common preventive mea-
sures, and optimization of oral rehydration therapy.
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